These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

4059 related items for PubMed ID: 28077397

  • 1. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ, Devous MD, Navitsky M, Lu M, Salloway S, Schaerf FW, Jennings D, Arora AK, McGeehan A, Lim NC, Xiong H, Joshi AD, Siderowf A, Mintun MA, 18F-AV-1451-A05 investigators.
    Brain; 2017 Mar 01; 140(3):748-763. PubMed ID: 28077397
    [Abstract] [Full Text] [Related]

  • 2. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.
    Pontecorvo MJ, Devous MD, Kennedy I, Navitsky M, Lu M, Galante N, Salloway S, Doraiswamy PM, Southekal S, Arora AK, McGeehan A, Lim NC, Xiong H, Truocchio SP, Joshi AD, Shcherbinin S, Teske B, Fleisher AS, Mintun MA.
    Brain; 2019 Jun 01; 142(6):1723-1735. PubMed ID: 31009046
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.
    Schwarz AJ, Yu P, Miller BB, Shcherbinin S, Dickson J, Navitsky M, Joshi AD, Devous MD, Mintun MS.
    Brain; 2016 May 01; 139(Pt 5):1539-50. PubMed ID: 26936940
    [Abstract] [Full Text] [Related]

  • 7. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, O'Neil JP, Janabi M, Lazaris A, Cantwell A, Vogel J, Santos M, Miller ZA, Bettcher BM, Vossel KA, Kramer JH, Gorno-Tempini ML, Miller BL, Jagust WJ, Rabinovici GD.
    Brain; 2016 May 01; 139(Pt 5):1551-67. PubMed ID: 26962052
    [Abstract] [Full Text] [Related]

  • 8. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.
    Leuzy A, Smith R, Ossenkoppele R, Santillo A, Borroni E, Klein G, Ohlsson T, Jögi J, Palmqvist S, Mattsson-Carlgren N, Strandberg O, Stomrud E, Hansson O.
    JAMA Neurol; 2020 Aug 01; 77(8):955-965. PubMed ID: 32391858
    [Abstract] [Full Text] [Related]

  • 9. Relationships Between Cognition and Neuropathological Tau in Alzheimer's Disease Assessed by 18F Flortaucipir PET.
    Devous MD, Fleisher AS, Pontecorvo MJ, Lu M, Siderowf A, Navitsky M, Kennedy I, Southekal S, Harris TS, Mintun MA.
    J Alzheimers Dis; 2021 Aug 01; 80(3):1091-1104. PubMed ID: 33682705
    [Abstract] [Full Text] [Related]

  • 10. Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18.
    Devous MD, Joshi AD, Navitsky M, Southekal S, Pontecorvo MJ, Shen H, Lu M, Shankle WR, Seibyl JP, Marek K, Mintun MA.
    J Nucl Med; 2018 Jun 01; 59(6):937-943. PubMed ID: 29284675
    [Abstract] [Full Text] [Related]

  • 11. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A, Sakayori T, Kawashima Y, Higuchi M, Suhara T, Mizumura S, Mintun MA, Skovronsky DM, Honjo K, Ishihara K, Kumita S, Suzuki H, Okubo Y.
    Int J Geriatr Psychiatry; 2015 May 01; 30(5):505-13. PubMed ID: 25043833
    [Abstract] [Full Text] [Related]

  • 12. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
    Bejanin A, Schonhaut DR, La Joie R, Kramer JH, Baker SL, Sosa N, Ayakta N, Cantwell A, Janabi M, Lauriola M, O'Neil JP, Gorno-Tempini ML, Miller ZA, Rosen HJ, Miller BL, Jagust WJ, Rabinovici GD.
    Brain; 2017 Dec 01; 140(12):3286-3300. PubMed ID: 29053874
    [Abstract] [Full Text] [Related]

  • 13. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
    Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, Grundman M, Sabbagh MN, Sadowsky CH, Fleisher AS, Carpenter A, Clark CM, Joshi AD, Mintun MA, Skovronsky DM, Pontecorvo MJ, AV45-A11 Study Group.
    Neurology; 2012 Oct 16; 79(16):1636-44. PubMed ID: 22786606
    [Abstract] [Full Text] [Related]

  • 14. Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β.
    Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Chamoun M, Savard M, Thomas E, Kang MS, Lussier F, Tissot C, Parsons M, Qureshi MNI, Vitali P, Massarweh G, Soucy JP, Rej S, Saha-Chaudhuri P, Gauthier S, Rosa-Neto P.
    JAMA Neurol; 2020 Apr 01; 77(4):470-479. PubMed ID: 31860000
    [Abstract] [Full Text] [Related]

  • 15. Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.
    Cody KA, Langhough RE, Zammit MD, Clark L, Chin N, Christian BT, Betthauser TJ, Johnson SC.
    Brain; 2024 Jun 03; 147(6):2144-2157. PubMed ID: 38667631
    [Abstract] [Full Text] [Related]

  • 16. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
    Lin KJ, Hsiao IT, Hsu JL, Huang CC, Huang KL, Hsieh CJ, Wey SP, Yen TC.
    Eur J Nucl Med Mol Imaging; 2016 Jul 03; 43(7):1304-14. PubMed ID: 27003417
    [Abstract] [Full Text] [Related]

  • 17. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
    Ossenkoppele R, Smith R, Mattsson-Carlgren N, Groot C, Leuzy A, Strandberg O, Palmqvist S, Olsson T, Jögi J, Stormrud E, Cho H, Ryu YH, Choi JY, Boxer AL, Gorno-Tempini ML, Miller BL, Soleimani-Meigooni D, Iaccarino L, La Joie R, Baker S, Borroni E, Klein G, Pontecorvo MJ, Devous MD, Jagust WJ, Lyoo CH, Rabinovici GD, Hansson O.
    JAMA Neurol; 2021 Aug 01; 78(8):961-971. PubMed ID: 34180956
    [Abstract] [Full Text] [Related]

  • 18. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N, Chételat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL, AIBL Research Group.
    Brain; 2012 Jul 01; 135(Pt 7):2126-39. PubMed ID: 22628162
    [Abstract] [Full Text] [Related]

  • 19. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.
    Hake A, Trzepacz PT, Wang S, Yu P, Case M, Hochstetler H, Witte MM, Degenhardt EK, Dean RA, Alzheimer's Disease Neuroimaging Initiative.
    Alzheimers Dement; 2015 Aug 01; 11(8):986-93. PubMed ID: 25916563
    [Abstract] [Full Text] [Related]

  • 20. Association of amyloid-β CSF/PET discordance and tau load 5 years later.
    Reimand J, Collij L, Scheltens P, Bouwman F, Ossenkoppele R, Alzheimer's Disease Neuroimaging Initiative.
    Neurology; 2020 Nov 10; 95(19):e2648-e2657. PubMed ID: 32913020
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 203.